PROSPECTIVE MULTICENTER STUDY FOR TREATMENT OF CHRONIC MYELOCYTIC-LEUKEMIA - COMPARISON OF BUSULFAN, HYDROCYUREA AND INTERFERON ALPHA (UPDATE APRIL, 1990)

HEHLMANN, R and HEIMPEL, H and HEINZE, B and GEORGII, A and KOLB, HJ and HOSSFELD, DK and VONWUSSOW, P and HOCHHAUS, A and GRIESSHAMMER, M and DIEHL, V and WICKRAMANAYAKE, PD and GALLMEIER, WM and FALGE, C and ESSERS, U and BERGMANN, L and MEYER, P and WALTHER, F and KANZ, L and QUEISSER, U and HOHNLOSER, J and WESTERHAUSEN, M and KLEEBERG, UR and HEILEIN, A and KABISCH, A and HEISS, F and ZIMMERMANN, R and MEURET, G and TICHELLI, A and BERDEL, WE and SCHMITZ, N and TIGGES, FI and EIMERMACHER, H and SCHMID, L and LOFFLER, H and PRALLE, H and QUEISSER, W and BURKHARDT, R and ANSARI, H and HASFORD, J (1991) PROSPECTIVE MULTICENTER STUDY FOR TREATMENT OF CHRONIC MYELOCYTIC-LEUKEMIA - COMPARISON OF BUSULFAN, HYDROCYUREA AND INTERFERON ALPHA (UPDATE APRIL, 1990). ONKOLOGIE, 14 (1). 66-&. ISSN 0378-584X,

Full text not available from this repository.

Abstract

In a multicenter study it is being determined, whether the use of hydroxyurea or of interferon alpha instead of busulfan prolongs the chronic phase of Philadelphia-positive CML. Additional goals are the examination, whether the types of disease evolution and the terminal phases differ between the treatment groups, and the prospective recognition of prognostic criteria for the duration of the chronic phase of CML. By September 5, 1990, 593 CML-patients had been randomized, 221 for busulfan, 228 for hydroxyurea and 144 for interferon alpha. The average age is about 51 years. By April 30, 1990, 106 patients had reached the end of the chronic phase, 126 had died. The median survival of Philadelphia-positive patients was 3.95 years, that of all patients 3.75 years. The median observation time of all patients was 1.34 years (mean 1.60 years). At present, no significant difference in survival is recognizable between the three treatment arms, although fewer adverse effects have been observed in the hydroxyurea arm.

Item Type: Article
Uncontrolled Keywords: CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC GRANULOCYTIC-LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; BONE-MARROW TRANSPLANTATION; PHILADELPHIA-CHROMOSOME; C-ABL; COMBINATION CHEMOTHERAPY; PROGNOSTIC FEATURES; GROUP-B; HYDROXYUREA; CHRONIC MYELOCYTIC LEUKEMIA; BUSULFAN; HYDROXYUREA; INTERFERON ALPHA; DURATION OF CHRONIC PHASE; PHASE-III-TRIAL
Depositing User: Dr. Gernot Deinzer
Last Modified: 19 Oct 2022 08:46
URI: https://pred.uni-regensburg.de/id/eprint/55102

Actions (login required)

View Item View Item